NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Repligen Corp. RGEN
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$738.3M
▲ 16.4% vs FY2024
EPS · FY25
$0.86
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
2.4%
Net margin · FY25
6.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 738.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
7 cents of every revenue dollar became profit this year.
Per share
USD 0.86
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
2.4%
Return on equity, FY2025
ROE
Operating margin7.5%
Net margin6.6%
Return on assets1.7%
Each USD of equity produced 2 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -3.2M
Share of profit0.0%
Consecutive raises—
Growth
+15.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.7%
+15.0%
+24.3%
+24.6%
Net income
−35.9%
−4.0%
+18.0%
EPS, diluted
−35.7%
−5.0%
+11.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+2.9%
Change, 10 years+70.9%
The share count grew 3% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.9B
total assets, end of FY2025
Total assetsUSD 2.9B
EquityUSD 2.1B
CashUSD 566.0M
Gross debtUSD 542.2M
Net debtUSD -23.8M
Current ratio8.37×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.7
0.6
0.6
0.8
0.7
0.4
0.3
0.2
0.1
0.1
0.1
0.1
0.1
0.1
·
0.0
0.0
Operating income $B
0.1
−0.0
0.0
0.2
0.2
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
−0.0
−0.0
EBITDA $B
0.1
−0.0
0.1
0.2
0.2
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
·
Income tax $B
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
·
−0.0
Net income $B
0.0
−0.0
0.0
0.2
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.86
−0.46
0.63
3.24
2.24
1.11
0.44
0.37
0.72
0.34
0.28
0.25
0.50
0.45
·
0.00
−0.13
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
2.4
−1.3
1.8
10.2
7.8
4.6
2.6
2.8
7.5
8.0
8.0
8.3
19.1
18.9
−2.4
−0.1
−6.1
Shares out B
0.06
0.06
0.06
0.06
0.06
0.05
0.05
0.04
0.04
0.03
0.03
0.03
0.03
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed